# Inhaled Nitric Oxide and Neuroprotection in Premature Infants

> **NCT00515281** · PHASE2,PHASE3 · TERMINATED · sponsor: **University of Chicago** · enrollment: 273 (actual)

## Conditions studied

- Prematurity
- Bronchopulmonary Dysplasia
- Intraventricular Hemorrhage
- Periventricular Leukomalacia

## Interventions

- **DRUG:** inhaled nitric oxide
- **DRUG:** oxygen

## Key facts

- **NCT ID:** NCT00515281
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-05
- **Primary completion:** 2023-06-07
- **Final completion:** 2023-11-28
- **Target enrollment:** 273 (ACTUAL)
- **Why stopped:** The pace of patient enrolledment forced recruitment to stop after 273 patients.
- **Last updated:** 2024-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00515281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00515281, "Inhaled Nitric Oxide and Neuroprotection in Premature Infants". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00515281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*